Aldehyde metabolism is potentially linked to numerous diseases and conditions. The underlying body of independently derived research suggests a wide range of potential target diseases for ALDH modulators (both activators and inhibitors), including:
- Orphan indications
- Cardiovascular diseases such as pulmonary artery disease and ischemic heart damage
- Inhibition of cancer cell growth
- Radiation dermatitis
- Management of neurological disorders such as Parkinson's disease
Getting to the Heart of Protoemics
Alda-1 is an agonist and chemical chaperone for the common human aldehyde dehydrogenase 2 variant
Variant ALDH2 is associated with accelerated progression of bone marrow failure in Japanese Fanconi anemia patients
Activation of Aldehyde Dehydrogenase-2 Reduces Ischemic Damage to the Heart
ALDH2 Activator Inhibits Increased Myocardial Infarction Injury by Nitroglycerin Tolerance